Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
Launched by SCITECH PRODUTOS MEDICOS LTDA · Mar 19, 2018
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Prospective, multicenter, single arm registry to assess the safety and performance of Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer for the treatment of "real world" patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All individuals aged over 18 years who signed the informed consent and had lesions in native coronary arteries treated only with Inspiron Sirolimus-Eluting stent.
- Exclusion Criteria:
- • Saphenous vein grafts or Mammary lesions;
- • Individuals who have been treated within the last 6 months with another stent;
- • Acute myocardial infarction with ST segment elevation;
- • Chronic Total Occlusion
About Scitech Produtos Medicos Ltda
Scitech Produtos Médicos Ltda. is a leading Brazilian company specializing in the development and commercialization of innovative medical devices and healthcare solutions. With a strong commitment to enhancing patient outcomes and advancing medical technology, Scitech focuses on rigorous research and development, adhering to international regulatory standards. The company's portfolio includes cutting-edge products designed for various medical fields, emphasizing safety, efficacy, and user-friendly designs. Scitech's dedication to quality and innovation positions it as a trusted partner in the clinical trial landscape, contributing to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, , Brazil
São Paulo, , Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials